OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck. (February 2015) - Eriksen, J.G.; Maare, C.; Johansen, J.; Primdahl, H.; Evensen, J.; Kristensen, C.A.; Andersen, L.J.; Overgaard, J.